# US 2026/0062472 A1 · Bispecific antibody and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062472 A1
- Document ID: US20260062472A1
- Status: Published application
- Kind: A1
- Application number: 19/312,684
- Filed: 2025-08-28
- Published: 2026-03-05
- Earliest claimed: 2024-08-28
- Assignees: Earendil Labs Inc.
- Applicants: Earendil Labs Inc.
- Inventors: Hao RAN; Jian HUANG; Zhenping ZHU; Jian PENG; Liang TIAN
- Web page: https://patentgrep.com/patent/US20260062472A1

## CPC

- C07K 16/241: {Tumor Necrosis Factors}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/244: {Interleukins [IL]}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/64: comprising a combination of variable region and constant region components
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present application provides an isolated antigen-binding protein, comprising: a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the first binding domain and the second binding domain are different.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

An isolated antigen binding protein, comprising: a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO: 14.

### Claim 38 (depends on 37)

The isolated antigen binding protein according to claim 37, wherein HCDR3 comprises an amino acid sequence of any one of SEQ ID NOs: 15-18.

### Claim 39 (depends on 37)

The isolated antigen binding protein according to claim 37, wherein the VH comprises an HCDR2 comprising an amino acid sequence of SEQ ID NO: 5.

### Claim 40 (depends on 39)

The isolated antigen binding protein according to claim 39, wherein the HCDR2 comprises an amino acid sequence of any one of SEQ ID NOs: 6-13.

### Claim 41 (depends on 39)

The isolated antigen-binding protein according to claim 39, wherein the VH comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:1.

### Claim 42 (depends on 41)

The isolated antigen-binding protein according to claim 41, wherein the HCDR1 comprises an amino acid sequence of any one of SEQ ID NOs:2-4.

### Claim 43 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the VH of the first binding domain comprises the HCDR1 as set forth in SEQ ID NO:2, the HCDR2 as set forth in SEQ ID NO:6, and the HCDR3 as set forth in SEQ ID NO:15.

### Claim 44 (depends on 43)

The isolated antigen-binding protein according to claim 43, wherein the first binding domain further comprises a light chain variable region (VL), and the VL of the first binding domain comprising at least one light chain complementary determining region (LCDR), which comprises an amino acid sequence selected from the amino acid sequences shown in SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:44.

### Claim 45 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the first binding domain comprises the VH as set forth in SEQ ID NO:270.

### Claim 46 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the first binding domain comprises the VL as set forth in SEQ ID NO:271.

### Claim 47 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the VH of the second binding domain comprises the HCDR1 as set forth in SEQ ID NO: 264, the HCDR2 as set forth in SEQ ID NO: 265, and the HCDR3 as set forth in SEQ ID NO: 266.

### Claim 48 (depends on 47)

The isolated antigen-binding protein according to claim 47, wherein the VL of the second binding domain comprises the LCDR1 as set forth in SEQ ID NO: 267, the LCDR2 as set forth in SEQ ID NO: 268, and the LCDR3 as set forth in SEQ ID NO: 269.

### Claim 49 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the second antigen binding domain comprises a VL as set forth in SEQ ID NO: 166 and/or the second antigen binding domain comprises a VH as set forth in SEQ ID NO: 148.

### Claim 50 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the antigen-binding protein comprises the scFv of the first antigen binding domain or the scFv of the second antigen binding domain.

### Claim 51 (depends on 50)

The isolated antigen-binding protein according to claim 50, wherein the scFv of the first antigen-binding domain comprises a sequence as set forth in SEQ ID NO: 133.

### Claim 52 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the VL and VH of the second binding domain comprises the VH as set forth in SEQ ID NO:148 and VL as set forth in SEQ ID NO:166.

### Claim 53 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the first heavy chain is selected from the sequence shown in any one of SEQ ID NOs: 183-208 and/or the first light chain is selected from the sequence shown in any one of SEQ ID NOs: 175-182.

### Claim 54 (depends on 37)

The isolated antigen-binding protein according to claim 37, wherein the first antigen-binding domain comprises HCDR1 as set forth in SEQ ID NO: 2, HCDR2 as set forth in SEQ ID NO: 6, HCDR3 as set forth in SEQ ID NO: 15, LCDR1 as set forth in SEQ ID NO: 42, LCDR2 as set forth in SEQ ID NO: 43, and LCDR3 as set forth in SEQ ID NO: 44; and the second antigen-binding domain comprises HCDR1 as set forth in SEQ ID NO: 264, HCDR2 as set forth in SEQ ID NO: 265, HCDR3 as set forth in SEQ ID NO: 266, LCDR1 as set forth in SEQ ID NO: 267, LCDR2 as set forth in SEQ ID NO: 268, and LCDR3 as set forth in SEQ ID NO: 269.

### Claim 55 (depends on 54)

The isolated antigen-binding protein according to claim 54, wherein the first antigen-binding domain comprises a VH as set forth in SEQ ID NO: 270 and a VL as set forth in SEQ ID NO: 271; and the second antigen-binding domain comprises a VH as set forth in SEQ ID NO: 148 and a VL as set forth in SEQ ID NO: 166.

### Claim 56 (depends on 55)

The isolated antigen-binding protein according to claim 55, wherein the first antigen-binding domain comprises an scFv as set forth in SEQ ID NO: 133; and the second antigen-binding domain comprises the VH as set forth in SEQ ID NO: 148 and the VL as set forth in SEQ ID NO: 166.

### Claim 57 (depends on 55)

The isolated antigen-binding protein according to claim 55 comprising a light chain as shown in SEQ ID NO: 182 and heavy chain as shown in SEQ ID NO: 207.

### Claim 58

An isolated nucleic acid molecule encoding an antigen-binding protein comprising: a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO: 14.

### Claim 59 (depends on 58)

A host cell comprising an isolated nucleic acid according to claim 58.

### Claim 60 (depends on 37)

A pharmaceutical composition comprising an isolated antigen-binding protein according to claim 37, and a pharmaceutically acceptable carrier.

### Claim 61

A method for preparing an isolated antigen-binding protein, comprising culturing a host cell comprising one or more nucleic acids encoding an isolated antigen binding protein, comprising a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO: 14, and recovering the isolated antigen-binding protein.

### Claim 62

A method for treating a TL1A or IL-23 mediated disease or condition in a subject in need thereof, the metho comprising: administering an isolated antigen binding protein to the subject, an antigen binding protein comprising a first binding domain and a second binding domain, wherein the first binding domain specifically binds to TNF-like protein A (TL1A), and the second binding domain specifically binds to IL-23p19, wherein the first binding domain comprises a heavy chain variable region (VH), and the VH comprises an HCDR3 comprising an amino acid sequence of SEQ ID NO: 14, thereby treating the subject.

### Claim 63 (depends on 62)

The method according to claim 62, wherein the TL1A or IL-23 mediated disease or condition is an inflammatory disease selected from one of the following: allergy, ankylosing spondylitis, asthma, atopic dermatitis, autoimmune diseases or disorders, cancer, celiac disease, chronic obstructive pulmonary disease (COPD), chronic peptic ulcer, cystic fibrosis, diabetes (e.g., type 1 diabetes and type 2 diabetes), glomerulonephritis, gout, hepatitis (e.g., active hepatitis), an immune-mediated disease or disorder, inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis, myositis, osteoarthritis, pelvic inflammatory disease (PID), multiple sclerosis, neurodegenerative diseases of aging, periodontal disease (e.g., periodontitis), preperfusion injury transplant rejection, psoriasis, pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), rheumatic disease, scleroderma, sinusitis, tuberculosis.

### Claim 64 (depends on 62)

The method according to claim 62, wherein the TL1A or IL-23 mediated disease or condition is an autoimmune disease selected from one of the following: achalasia, Addison's disease, Adult Stil's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, autoimmune angioedema, autoimmune familial autonomic dysfunction, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal and neuronal neuropathy (AMAN), Barlow disease (Balódisease), Behcet's disease, benign mucous membrane pemphigoid, bullous pemphigoid, Castleman's disease (Castleman disease (CD), celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss syndrome (CSS) or eosinophilic granulomatous disease (EGPA), cicatricial pemphigoid, and Cogan's syndrome), cold agglutinin disease, congenital heart block, coxsackienew myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, primary mixed cryoglobulinemia, Evans syndrome, fibromyalgia, fibrotic alveolitis, giant cell arteritis (temporal arteritis), giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barre syndrome syndrome), Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gravilens or pemphigoid gestationum (PG), hidradenitis suppurativa (HS) (paradoxical acne), hypogammaglobulinemia, IgA nephropathy, IgG4-associated sclerotic disease, immune thrombocytopenic purpura (ITP), Inclusion body myositis (IBM), interstitial cystitis (IC), juvenile arthritis, juvenile diabetes mellitus (type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, lignoconjunctivitis, linear IgA disease (LAD), lupus, chronic Lyme disease (Lyme disease chronic), Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, recurrent rheumatism (PR), PandAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, ciliary planitis (peripheral uveitis), Parsonage-Tumer syndrome), pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndrome type I, II, type III, polymyalgia rheumatica, polymyositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cirrhosis, primary sclerosing cholangitis, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red blood cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm and testicular autoimmunity, stiff-person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac's syndrome syndrome), sympathetic ophthalmia (SO), Takayasu's arteritis, temporal arteritis/giant cell arteritis, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome (THS), transverse myelitis, type 1 diabetes mellitus, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, Vitiligo and Vogt-Koyanagi-Harada disease.

### Claim 65 (depends on 62)

The method according to claim 62, wherein the TL1A or IL-23 mediated disease or condition is a cancer selected from one or more of the following: adenoid cystic carcinoma, adrenal carcinoma, amyloidosis, anal cancer, ataxia-telangiectasia, atypical nevus syndrome, basal cell carcinoma, cholangiocarcinoma, Birt Hogg Dube syndrome, bladder cancer, bone cancer, brain tumor, breast cancer, male breast cancer, carcinoid tumor, cervical cancer, colorectal cancer, ductal cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), HER2-Positive Breast Cancer, Pancreatic Islet Cell Tumor, Juvenile Polyposis Syndrome, Kidney Cancer, Laryngeal Cancer, Leukemia—Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia AML, Adult Leukemia, Childhood Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Liver Cancer, Lobular Carcinoma, Lung Cancer, Small Cell Lung Cancer (SCLC), Non-small cell lung cancer (NSCLC), Hodgkin's lymphoma (Lymphoma-Hodgkin's), non-Hodgkin's lymphoma (Lymphoma-Non-Hodgkin's), malignant glioma, melanoma, meningioma, multiple myeloma, myelodysplastic syndrome (MDS), nasopharyngeal carcinoma, neuroendocrine tumor, oral cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic neuroendocrine tumor, parathyroid carcinoma, penile cancer, peritoneal cancer, Peutz-Jeghers syndrome, pituitary tumors, polycythemia vera, prostate cancer, renal cell carcinoma, retinoblastoma, salivary gland carcinoma, sarcoma, Sarcoma-Kaposi, skin cancer, small bowel cancer, stomach cancer, testicular cancer, thymoma, thyroid cancer, uterine (endometrial) cancer, vaginal cancer, and Wilms' Tumor.
